P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Summary

This is a phase 3 double-blind clinical trial arm to test Ropeginterferon alfa-2b (P1101) in adult patients with Primary Myelofibrosis (PMF) at early stage or low to medium risk. Participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 weeks. The ratio of study drug to placebo group is 2:1.

Timeline

Start

2025-07-18

Primary completion

2027-09-30

Completion

2028-09-30

Drugs

Indications